Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Irene  Cortes-Puch
Organization: EICOSIS, LLC
Fiscal Year: 2024
Award: $2,141,943
Funding agency: National Institute on Drug Abuse

Summary/Abstract
EicOsis is developing a first-in-class analgesic with efficacy against neuropathic pain that will
replace and dose spare opioids and thus prevent opioid use disorders (OUDs). The target of the
small molecule inhibitor EC5026 is the soluble epoxide hydrolase, a master regulatory enzyme
that modulates the activity of endogenous bioactive lipids. The development of EC5026 is
currently in progress and progressing to an IND filing and is poised to have a high impact in
treating chronic pain in humans. In this proposal we outline aims to reach the next steps in
clinical human clinical trials with EC5026 as well as additional preclinical studies to expand the
efficacy into models of chronic pain conditions presenting in humans which are most frequently
treated with opioids. Additionally, we propose detailed pharmacokinetic, metabolism and
distribution studies that will provide the required information for advanced clinical trials
examining efficacy in humans. We also propose to optimize a formulation to meet these needs.
All of these individual aims are structured to meet 2 year milestones (UG3) and continue to the
next planned steps in development (UH3) as these milestones are met. EicOsis is meeting
current development goals and EC5026 is well positioned to meet the urgent need of reducing
opioid use because even given the updated strategy to treating pain with multimodal
approaches, pharmaceuticals are the foundation of treating pain. EC5026 represents a first-in-
class analgesic that is not an opioid nor a NSAID but offers effective pain relief for chronic
neuropathic pain.

Terms: <Accidents><Analgesic Agents><Analgesic Drugs><Analgesic Preparation><Analgesics><Anodynes><Antinociceptive Agents><Antinociceptive Drugs><Attenuated><Biochemical><Bioequivalence><Biological><Biological Markers><Canine Species><Canis familiaris><Capsules><Cessation of life><Chemicals><Clinical><Clinical Equivalency><Clinical Trials><Combined Modality Therapy><Common Rat Strains><Cyclic GMP><Data><Death><Development><Dogs><Dogs Mammals><Dose><Drug Kinetics><Ensure><Enzyme Gene><Enzymes><Epoxide Hydrases><Epoxide Hydratases><Epoxide hydrolase><Fasting><Fatty Acids><Formulation><Foundations><Generic Equivalency><Goals><Guanosine Cyclic Monophosphate><Human><Individual><Intermediary Metabolism><Lipids><Low Back Ache><Low Back Pain><Low Backache><Lumbago><Marketing><Medicine><Metabolic Processes><Metabolism><Modeling><Modern Man><Monitor><Morbidity><Morbidity - disease rate><Multimodal Therapy><Multimodal Treatment><NIH><NINDS><NSAIDs><National Institute of Neurological Diseases and Stroke><National Institute of Neurological Disorders and Stroke><National Institutes of Health><Neuropathy><Non-Steroidal Anti-Inflammatory Agents><Opiates><Opioid><Opioid Analgesics><Pain><Pain Control><Pain Therapy><Pain management><Painful><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Phase><Phase 1a Trial><Phase Ia Trial><Polyunsaturated Fatty Acids><Position><Positioning Attribute><Preparation><Rat><Rats Mammals><Rattus><Refractory><Rodent><Rodentia><Rodents Mammals><SCI Patients><Safety><Sampling><Spinal Cord Trauma><Spinal Trauma><Spinal cord injured><Spinal cord injury><Spinal cord injury patients><Structure><Testing><Therapeutic Equivalency><Traumatic Myelopathy><Treatment Efficacy><United States><United States National Institutes of Health><Update><Work><addiction><addictive disorder><attenuate><attenuates><behavior outcome><behavioral outcome><bio-markers><biologic><biologic marker><biomarker><cGMP><canine><capsule><chronic neuropathic pain><chronic pain condition><chronic pain control><chronic pain disorder><chronic pain intervention><chronic pain management><chronic pain relief><chronic pain therapy><chronic pain treatment><chronic painful condition><clinical development><combination therapy><combined modality treatment><combined treatment><comparable efficacy><comparative efficacy><compare efficacy><design><designing><determine efficacy><developmental><domestic dog><drug bioequivalence><drug bioequivalent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><fasted><fasts><human subject><inflammatory pain><inhibitor><intervention efficacy><lead candidate><licit opioid><manufacture><meeting><meetings><mortality><multi-modal therapy><multi-modal treatment><multi-modality><multimodality><neuropathic><neuropathic pain><non-steroidal anti-inflammatory drugs><novel><opiate analgesia><opiate analgesic><opiate consumption><opiate drug use><opiate intake><opiate medication><opiate overdose><opiate pain medication><opiate pain reliever><opiate related overdose><opiate use><opiate use disorder><opioid analgesia><opioid anesthetic><opioid consumption><opioid drug overdose><opioid drug use><opioid induced overdose><opioid intake><opioid intoxication><opioid medication><opioid medication overdose><opioid overdose><opioid pain medication><opioid pain reliever><opioid painkiller><opioid poisoning><opioid related overdose><opioid sparing><opioid toxicity><opioid use><opioid use disorder><pain killer><pain medication><pain model><pain relief><pain reliever><pain treatment><painful neuropathy><painkiller><patient population><pharmaceutical><phase 2 designs><phase II designs><pre-clinical><pre-clinical efficacy><pre-clinical safety><pre-clinical study><preclinical><preclinical efficacy><preclinical safety><preclinical study><preparations><prescribed opiate><prescribed opioid><prescription opiate><prescription opioid><prevent><preventing><programs><relieve pain><safety assessment><safety study><safety testing><side effect><small molecular inhibitor><small molecule inhibitor><therapeutic efficacy><therapy efficacy><treat chronic pain>